Latent View Analytics Strong Fiscal Year 2026 Performance and Leadership Reappointments

Latent View Analytics has reported strong financial growth for the fiscal year ended March 31, 2026, with consolidated revenue reaching ₹10,601.92 million and a net profit of ₹2,021.24 million. Alongside these financial achievements, the company announced the reappointment of key leadership figures and the continuation of M/s. BDO India LLP as Internal Auditors for the next two fiscal years.

Financial Highlights for FY 2026

Latent View Analytics has demonstrated robust performance for the financial year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹10,601.92 million, marking significant growth over the previous year’s ₹8,478.43 million. Consolidated net profit for the year stood at ₹2,021.24 million, up from ₹1,734.97 million in the prior year. For the final quarter (Q4), the company posted revenue of ₹2,886.18 million and a net profit of ₹550.62 million.

Strategic Reappointments

During the board meeting held on May 16, 2026, the company approved several key leadership reappointments. Dr. R. Raghuttama Rao and Mr. Reed Cundiff have been reappointed as Independent Directors for a second term of five consecutive years. Additionally, the company’s founders, Mr. A.V. Venkatraman and Ms. Pramadwathi Jandhyala, have been reappointed as Whole Time Directors for another five-year term, reflecting a commitment to stable, long-term leadership.

Internal Audit and Strategic Outlook

In addition to leadership changes, the board confirmed the reappointment of M/s. BDO India LLP as Internal Auditors for the financial years 2026-2027 and 2027-2028. Regarding ongoing strategic initiatives, the company continues to navigate the acquisition of Decision Point Private Limited, noting that the final resolution regarding the interpretation of share purchase agreements is currently in progress. Furthermore, the company has recently expanded its footprint in the healthcare AI sector through a strategic investment in Healtheon AI INC.

Source: BSE

Previous Article

Akums Drugs and Pharmaceuticals Ltd Update on Haridwar Manufacturing Operations

Next Article

Aarti Drugs Limited Reports Strong Q4 and FY26 Performance Amid Strategic Scaling